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Summary
The DAX1 protein is an orphan nuclear hormone re-
ceptor based on sequence similarity in the putative li-
gand-binding domain (LBD). DAX1 mutations result in
X-linked adrenal hypoplasia congenita (AHC). Our ob-
jective was to identify DAX1 mutations in a series of
families, to determine the types of mutations resulting
in AHC and to locate single–amino-acid changes in a
DAX1 structural model. The 14 new mutations iden-
tified among our 17 families with AHC brought the total
number of families with AHC to 48 and the number of
reported mutations to 42; 1 family showed gonadal mo-
saicism. These mutations included 23 frameshift, 12
nonsense, and six missense mutations and one single-
codon deletion. We mapped the seven single–amino-acid
changes to a homology model constructed by use of the
three-dimensional crystal structures of the thyroid-hor-
mone receptor and retinoid X receptor a. All sin-
gle–amino-acid changes mapped to the C-terminal half
of the DAX1 protein, in the conserved hydrophobic core
of the putative LBD, and none affected residues expected
to interact directly with a ligand. We conclude that most
genetic alterations in DAX1 are frameshift or nonsense
mutations and speculate that the codon deletion and
missense mutations give insight into the structure and
function of DAX1.
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Introduction
The X-linked cytomegalic form of adrenal hypoplasia
congenita (AHC; MIM 300200 [http://www.ncbi.
nlm.nih.gov/omim]) is caused by loss of DAX1 (dosage-
sensitive sex-reversal adrenal hypoplasia congenita on
the X chromosome, gene 1) function, through deletion
of the entire gene (McCabe 1995) or intragenic muta-
tions with profound effects (Muscatelli et al. 1994; Zan-
aria et al. 1994; Guo et al. 1995b, 1996a; Habiby et al.
1996; Nakae et al. 1996; Yanase et al. 1996; Schwartz
et al. 1997; Takahashi et al. 1997). AHC is an inborn
error in the development (Epstein 1995) of the adrenal
gland, characterized by marked underdevelopment or
absence of the permanent adult zone of the adrenal cor-
tex and by structural disorganization of the fetal cortex
(Marsden and Zakhour 1978; Seltzer et al. 1985). In
addition to adrenal insufficiency with low glucocorticoid
and mineralocorticoid levels, affected males also have
hypogonadotropic hypogonadism (HH) (Prader et al.
1975; Golden et al. 1977; Zachmann et al. 1980; Hay
et al. 1981; Virdis et al. 1983; Martin andMartin 1985).
Previous clinical investigations into the etiology of HH
in patients with AHC indicated mixed results regarding
hypothalamic and/or pituitary origin (Gordon et al.
1984; Kruse et al. 1984; Kikuchi et al. 1987; Bovet et
al. 1988; Partsch and Sippell 1989; Kletter et al. 1991;
McCabe 1996). Recent results have resolved this con-
troversy by showing that DAX1 acts at the levels of both
the hypothalamus and the pituitary, to mediate pubertal
development (Habiby et al. 1996), consistent with the
pituitary and hypothalamic expression of DAX1 in hu-
mans (Guo et al. 1995a) and mouse (Ikeda et al. 1996;
Swain et al. 1996).
DAX1 is an orphan member of the nuclear hormone-
receptor superfamily, on the basis of sequence conser-
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vation in the C-terminal portion of the protein, which
is the putative ligand-binding domain (LBD) (Zanaria
et al. 1994; Burris et al. 1996). The orphan receptor
with the closest apparent relationship to DAX1 is the
small heterodimer partner (SHP) that interacts with and
blocks transactivation of the retinoic acid receptor
(RAR), the retinoid X receptor (RXR), and the thyroid-
hormone receptor (TR), suggesting a role for SHP in
negative regulation of receptor-dependent signaling (Seol
et al. 1996). The N-terminal portion of DAX1 contains
3.5 repeats of a 65–67-amino-acid motif and forms two
putative zinc-finger domains, the cysteines of which are
absolutely conserved in the human and murine se-
quences (Zanaria et al. 1994; Guo et al. 1995b, 1996b;
Burris et al. 1996; Swain et al. 1996). A steroidogenic
factor 1 (SF1) response element (SF1-RE) is present in
the DAX1 promoter (Guo et al. 1996a), is conserved in
the murine Ahch promoter (Guo et al. 1996b; Swain et
al. 1996), and binds SF1 in vitro (Burris et al. 1995).
SF1 enhances expression of reporter-gene constructs
containing the DAX1 promoter, in human adrenal cor-
tical carcinoma NCI-H295 cells (Yu et al. 1996; Vilain
et al. 1997) but not in constructs containing the mouse
Ahch promoter transfected into Y1 adrenal cortical or
MA-10 Leydig cells (Ikeda et al. 1996), and deletion of
the SF1-RE region or of the 9-bp SF1-RE in the DAX1
promoter eliminates SF1 enhancement of these reporter-
gene constructs (Yu et al. 1996; Vilain et al. 1997). Re-
cent data demonstrate direct interaction of DAX1 with
SF1, and cotransfection with DAX1 and SF1 inhibits
SF1-mediated transactivation (Ito et al. 1997). Whereas
the DAX1 amino acids involved in the DAX1-SF1 pro-
tein-protein interaction appear to reside in the N-ter-
minal half of the protein, the inhibitory activity of DAX1
localizes to the C-terminal portion. Therefore, although
limited information is available on functional elements
within the promoter and functional domains of the pro-
tein, additional structure-function insights are required,
to understand the role of the DAX1 gene in the devel-
opment and function of the hypothalamic-pituitary-ad-
renal/gonadal axis.
The purpose of the current investigation was to iden-
tify mutations within the DAX1 gene, in order to de-
termine the types of intragenic mutations responsible for
AHC and to identify the positions of single–amino-acid
changes in a structural model of DAX1, to attempt to
gain a better understanding of the relationship between
its structure and function. Of the 17 families reported
here, only 3 had missense mutations, and 1 had a single-
codon deletion; the others had frameshift or nonsense
mutations. These four single–amino-acid changes, plus
three others reported elsewhere (Muscatelli et al. 1994;
Schwartz et al. 1997; Takahashi et al. 1997), all map
within the C-terminal portion of DAX1 and, by ho-
mology with the crystal structures of the TR (Wagner
et al. 1995) and RXRa (Bourguet et al. 1995), lie within
the conserved hydrophobic core of the putative LBD
involved in hormone-independent activities such as in-
termolecular dimerization.
Patients and Methods
Patients
The protocols for sample collection and analysis were
approved by the institutional review boards at Baylor
College of Medicine and UCLA School of Medicine.
Specimens, including whole blood for DNA preparation
and/or for lymphoblastoid cell-line generation, were col-
lected from males with clinical features of AHC and
from their family members, after informed consent was
obtained. The affected males who were old enough also
exhibited HH.
SSCP Analysis
SSCP analysis was performed in accordance with the
method described by Orita et al. (1989). The coding
portion of the DAX1 gene and the contiguous genomic
intron-exon boundaries were divided into 10 overlap-
ping regions, which were amplified, denatured, electro-
phoresed, and autoradiographed as described elsewhere
(Guo et al. 1996a). PCR products with anomalous mo-
bility in the gel were sequenced.
DNA Sequence Analysis
For the identification of mutations, after SSCP, se-
quencing of PCR-amplified DNA fragments was per-
formed by manual Sanger dideoxy-chain termination
(Sanger et al. 1977), by use of the Sequenase version 2.0
DNA sequencing kit (U.S. Biochemical) or by automated
DNA sequencing with an ABI 377 automated DNA se-
quencer, with cycle sequencing and dye-terminator
chemistry. Direct genomic sequencing without prior
SSCP also was used to identify mutations; the primers
used for direct sequencing have been reported elsewhere
or were derived from the genomic sequence (Guo et al.
1996a). Probes used for dot-blot confirmation of mu-
tation 16, 518del23bp (table 1), by allele-specific oli-
gonucleotide hybridization (fig. 1) were the following:
normal, 5′-GCT CCT ACT TCG CGC AGA GG-3′; and
mutant, 5′-TAC CCC CTG GCC CAC CAC GC-3′. In
the family with gonadal mosaicism (mutation 16; table
1 and fig. 1), the matrilineal relationships of the affected
males and the carrier females to individual I-1 were con-
firmed by automated sequencing of the mitochondrial
D-loop (Mumm et al. 1997).
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Table 1
Mutations in the DAX1 Gene
Mutation
Type and No. Mutation Patient Reference
Frameshift:
1 749delGTCCACAGGTG MIN/MEN Zanaria et al. (1994)
2 547insACCC 2957 Zanaria et al. (1994)
3 785 complex deletion/
insertion
MA Muscatelli et al. (1994)
4 315insT LB/LM Muscatelli et al. (1994)
5 550delAA 2791 Muscatelli et al. (1994)
6 562insCAGG 3741 Muscatelli et al. (1994)
7 273CG-T 2094 Muscatelli et al. (1994)
8 1292delG RE Guo et al. (1995b)
TP Guo et al. (1995b)
9 839delT TS Yanase et al. (1996)
10 1267insCC DT Guo et al. (1996a)
11 154delGA JLB Guo et al. (1996a)
12 935delC Case 6 Nakae et al. (1996)
13 1376delAT, insG Case 4 Nakae et al. (1996)
14 Complex deletion/substi-
tution: 985delG,
G987A
JW Habiby et al. (1996)
15 1250insGGAT MH Habiby et al. (1996)
16 518del23bp RR/RD This study
17 543delA NW This study
18 754delC MKA This study
19 416insA KK This study
20 942insAC EC This study
21 375insGCCC JDW This study
22 501delA HD This study
23 629insG JWC This study
Nonsense:
24 W235X BF Zanaria et al. (1994)
2065 Muscatelli et al. (1994)
JF This study
25 Q283X MT/CB Muscatelli et al. (1994)
26 W369X AO/LS Muscatelli et al. (1994)
27 L263X BR Muscatelli et al. (1994)
28 W172X 3743/3744 Muscatelli et al. (1994)
29 W171X TK Yanase et al. (1996)
RM This study
30 Y91X PS/RH Guo et al. (1996a)
Case 2 Nakae et al. (1996)
31 Q395X Case 1 Nakae et al. (1996)
32 Y271X Case 5 Nakae et al. (1996)
33 S153X BA/BB This study
34 Q357X GF This study
35 Q252X DT/ST This study
Missense:
36 R267P 2687/2688 Muscatelli et al. (1994)
37 N440I From Greenland Schwartz et al. (1997)
38 A300V From Akita, Japan Takahashi et al. (1997)
39 R425G TC/NC This study
40 V385G LRP This study
41 E377K EM This study
Codon deletion:
42 dV269 (in-frame deletion) 2115 Muscatelli et al. (1994)
AS This study
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Figure 1 Family with frameshift mutation 16 (table 1) caused
by 23-bp deletion, exhibiting gonadal mosaicism. Allele-specific oli-
gonucleotide hybridization confirmed sequence results and showed
that individual I-1, the mother of a carrier daughter (II-1) and an
affected son (II-2), did not carry the mutant allele and, therefore,
exhibited gonadal mosaicism. B  negative control; and N  normal
individual.
Sequence Alignment and Computer Modeling
Sequence alignments and secondary-structure predic-
tion for human DAX1, mouse Ahch, mouse SHP, the rat
TRa (rTRa) isoform, and the human RXRa (hRXRa)
isoform were performed using PHD (European Molec-
ular Biology Laboratory [http://www.embl-heidel-
berg.de/predictprotein]) and were adjusted outside the
conserved helices (Rost and Sander 1994). The Homol-
ogy module in Insight II (Biosym Technologies) was used
to generate a model for the DAX1 LBD, on the basis of
the known structures of rTRa (Wagner et al. 1995) and
hRXRa (Protein Data Bank entry 1LBD [http://
www.nyu.edu/pages/mathmol/pdb.html]) (Bourguet et
al. 1995). The rTR and hRXR LBDs were superimposed
by use of the Ca atoms of hydrophobic core helices H1
(rTR residues I168–T178 and hRXR residues
V232–V242), H3–H5–H6 (rTR residues P254–R266
and hRXR residues K274–R316), H9 (rTR residues
D313–V322 and hRXR residues K364–I373), and H10
(rTR residues V335–N354 and hRXR residues
P386–K405) (root mean squared deviation of 1.03 A˚,
for 168 Ca; Wurtz et al. 1996). Coordinates for the
DAX1 LBD were generated for structurally conserved
regions, assigned by low root mean squared deviation
(!1.0 A˚), between rTRa and hRXRa. The loop between
helices H10 and H11, which assumes different confir-
mations in rTRa and hRXRa, was modeled on that in
hRXRa. Helix H1, which shows weak sequence identity
across the nuclear receptors, was tentatively assigned to
residues L196–H206. The model for the DAX1 LBD
consisted of residues L196–H206 (H1), V253–E307
(H3–H5–H6), and V358–I470 (H8–H9–H10–H11),
representing the hydrophobic core of the putative LBD.
Results
SSCP analysis and/or genomic sequencing of the cod-
ing portion of the DAX1 gene, as well as of the bound-
aries between the intron and exons 1 and 2, identified
mutations in 17 new families for which mutations had
not been documented previously (table 1). Among these
17 families, 8 had frameshifts, 5 had nonsense muta-
tions, 3 had missense mutations, and 1 exhibited an in-
frame triplet deletion resulting in loss of a single codon.
Fourteen of these mutations had not been observed pre-
viously; but one nonsense mutation, W235X, had been
reported twice before (Muscatelli et al. 1994; Zanaria
et al. 1994), another nonsense mutation, W171X, had
been observed once before (Yanase et al. 1996), and the
codon deletion, dV269, had been described by another
group (Muscatelli et al. 1994).
Initially, on the basis of previous work from our group
(Guo et al. 1996a), we screened for mutations, using
SSCP analysis. However, the size of the DAX1 coding
sequence, the simplicity of its two-exon genomic organ-
ization, and the improved sensitivity of direct sequencing
caused us to change our strategy from SSCP screening
to direct genomic sequencing as our primary mutation-
detection methodology, during the course of these in-
vestigations. All mutations were confirmed by at least
one other modality, alteration of restriction-enzyme
cleavage and/or dot-blot hybridization.
The family with the 23-bp frameshift mutation,
518del23bp (mutation 16; table 1), was evaluated by
direct sequencing and dot-blot hybridization (fig. 1). The
results from whole blood indicated that individual I-1,
whose son and daughter’s son had AHC, was not a
carrier. Blood samples were redrawn from each of the
family members, with extreme care taken during the la-
beling in the clinic and the laboratory, and the original
results were confirmed. The matrilineal relationships of
carrier females and affected males within this family to
individual I-1 were confirmed by the mitochondrial D-
loop sequence (data not shown). Two different buccal
brushings were collected from individual I-1, and no
evidence of the presence of the mutation was observed
in either sample (data not shown). Therefore, the results
in this family were consistent with gonadal mosaicism
for the DAX1 mutation in individual I-1, with the mu-
tation occurring at a time during her development such
that not all cell lineages were affected, but at least a
portion of the cells that gave rise to her ova were
involved.
The frameshift and nonsense mutations were distrib-
uted throughout the DAX1 coding region (fig. 2). How-
ever, the alterations resulting in single–amino-acid
changes that we observed during these investigations and
the other missense mutations—R267P (Muscatelli et al.
Zhang et al.: DAX1 Mutations Provide Structure-Function Insights 859
Figure 2 Diagram showing positions of the frameshift, nonsense, and missense mutations and the single-codon deletion, in a model of
the DAX1 protein. The frameshift and nonsense mutations are distributed throughout the molecule. The single–amino-acid alterations were
found to be located only in the C-terminal half of the protein, representing the putative LBD.
1994), N440I (Schwartz et al. 1997), and A300V (Tak-
ahashi et al. 1997)—were found only in the C-terminal
portion, which is the region that showed similarity to
the LBDs of other nuclear hormone receptors (figs. 2
and 3). We sought to determine whether there was any
pattern to single–amino-acid changes in a three-dimen-
sional model of the LBD, on the basis of homology with
rTRa1 (Wagner et al. 1995) and hRXRa (Bourguet et
al. 1995) (fig. 4).
In a proposed canonical fold for the nuclear receptors,
the hydrophobic core consists of a-helices H1,
H3–H5–H6, H9, H10, and H11 (Wurtz et al. 1996).
All the single–amino-acid alterations in these naturally
occurring DAX1 mutations—R267P, dV269, A300V,
E377K, V385G, R425G, and N440I (table 1)—mapped
within the hydrophobic core of the putative DAX1 LBD
(fig. 4B). Certain mutations affected residues predicted
to form intramolecular contacts in the DAX1 LBD. For
example, at residues E377 and R425, the glutamate and
arginine side chains formed a conserved charge pair link-
ing a-helices H9 and H11 (Wagner et al. 1995). Mu-
tations E377K and R425G would disrupt this linkage.
Residues homologuous to E377 were conserved abso-
lutely in related members of the nuclear-receptor super-
family (fig. 3), and a charge pair involving those residues
was observed in the crystal structures of the rTR, hRXR,
and human RAR (hRAR) LBDs (Bourguet et al. 1995;
Wagner et al. 1995; Wurtz et al. 1996). Two other mu-
tations, R267P and dV269, would cause structural per-
turbations in helix H3: mutation R267P inserted a helix-
breaking proline, and mutation dV269 altered the phase
of the helix. The mutations occurred either immediately
preceding or at the beginning of a highly conserved se-
quence signature for the typical nuclear-receptor LBD,
(FW)AKxhxPxFxxLxxxDQxxLL (Wurtz et al. 1996).
The motif provided the hydrophobic core for an unusual
structure, which is present in the rTR, hRXR, and hRAR
LBDs and is adopted by the loop between H3 and
H5–H6.
Mutations V385G and A300V affected buried hydro-
phobic residues. Mutation V385G replaced a buried hy-
drophobic residue in H9, a buried core helix, with a less
bulky residue that increased flexibility at this position.
Conversely, mutation A300V replaced a buried hydro-
phobic residue in helix H6, with a bulkier residue in a
tightly packed environment defined by a-helices H8 and
H9.
Finally, mutation N440I exchanged a hydrophilic side
chain for a hydrophobic side chain in a polar environ-
ment. Residue N440 occurred in H11, in a solvent-ex-
posed invagination, near the bend in H5–H6. Replace-
ment of the hydrophilic asparagine side chain for the
bulkier, hydrophobic isoleucine might lead to steric clash
with H5–H6.
The amino acid deletion and substitutions identified
in patients with AHC all involved residues that were
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Figure 3 Locations of single–amino-acid alterations, shown in
a sequence alignment of Ahch and DAX1, compared with the related
nuclear hormone receptors SHP, rTRa, and hRXRa. The missense
mutations and single-codon in-frame deletion are shown above the
comparison, in boldface, and the corresponding positions in each of
the aligned proteins also are given in boldface. The positions of the
helices discussed in the text are shown by dashed lines below the
comparisons.
conserved in human DAX1 and mouse Ahch (fig. 3)
(Guo et al. 1996b; Swain et al. 1996), consistent with
key structural and functional roles for these residues. In
fact, of the seven mutated amino acids, one residue
(V385) was conserved in one other, related nuclear hor-
mone receptor, two residues (A300 and R425) were con-
served in two others, and a third residue (E377) was
conserved in three others (fig. 3).
Discussion
We identified DAX1 mutations in individuals in 17
previously unreported families with AHC. Each of these
families had a different mutation, although three mu-
tations had been reported by others: W235X had been
described twice before (Muscatelli et al. 1994; Zanaria
et al. 1994), and dV269 and W171X each had been
observed by another group (Muscatelli et al. 1994; Yan-
ase et al. 1996). Therefore, these 17 families represent
14 new mutations in theDAX1 gene, bringing the totals
to 48 AHC families and 42 mutations identified in this
gene (Muscatelli et al. 1994; Zanaria et al. 1994; Guo
et al. 1995b, 1996a; Habiby et al. 1996; Nakae et al.
1996; Yanase et al. 1996; Schwartz et al. 1997; Taka-
hashi et al. 1997; this report); 1 mutation was observed
in 3 families, and 4mutations were observed in 2 families
each (table 1) (Muscatelli et al. 1994; Zanaria et al.
1994; Guo et al. 1995b, 1996a; Nakae et al. 1996; Yan-
ase et al. 1996; this report). For each of these five mu-
tations, for which more than one family is described,
our group determined a mutation in one or both of the
families (Guo et al. 1995b, 1996a; this report). To our
knowledge, the families in our study are unrelated to
the families reported with identical mutations, by others,
and ethnicity differed for some families with the same
mutation. We had identified previously two unrelated
families with the 1292delG frameshift mutation, and
evaluation of the mitochondrial D-loop sequence
(Mumm et al. 1997) showed substantial differences be-
tween the two probands, confirming that their families
were not closely related (Y.-H. Zhang, B.-L. Huang, and
E. R. B. McCabe, unpublished data).
The majority of the mutations described, to date, in-
volved introduction of a new, premature stop codon in
the DAX1 transcript, by frameshift or nonsense muta-
tions, resulting in a shorter deduced protein product (ta-
ble 1). A total of 23 frameshift mutations have been
reported in 24 families, and 12 nonsense mutations have
been reported in 16 families. Only seven single–amino-
acid alterations have been described: six missense mu-
tations in 6 families and a single-codon deletion in 2
families.
In addition to the observation of identical mutations
in apparently unrelated families, one example of gonadal
mosaicism was documented. The mother of an affected
son and an obligate carrier daughter did not evidence
the 23-bp deletion observed in her affected son and
grandson and in her carrier daughter and granddaughter.
Four different samples, representing two blood speci-
mens drawn at separate times and two independent buc-
cal brushings, were examined, and none showed de-
tectable mosaicism. Documentation of apparent gonadal
mosaicism in this family has important implications for
genetic counseling of other families, with DAX1 mu-
tations, in which one affected male is the offspring of a
noncarrier female. The counselor must acknowledge to
the consultand that the existence of gonadal mosaicism
in the family reported in this study indicates the possi-
bility that the consultand may have another affected
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Figure 4 Models of LBDs for rTRa and human DAX1, showing
subdomain structure and the impact of DAX1 mutations on structure.
A, Ribbon diagram of the rTRa isoform, as an example of a nuclear
receptor LBD. The black, horizontal line shows the division of the
receptor into two subdomains: the structural subdomain, containing
the hydrophobic core of the LBD, is above the line, and the ligand-
binding subdomain is below the line. Shown within the hydrophobic
core are the highly conserved residues discussed in the text. The LBD
sequence signature, (FW)AKxhxPxFxxLxxxDQxxLL (Wurtz et al.
1996), runs from H3 to H5–H6; in rTRa, the specific sequence is 232-
FAKKLPMFSELPCEDQIILL-251. The conserved charge pair between
H9 and H11 also is shown; in rTRa, the specific residues are E315
and H358. B, Model of hydrophobic core of the human DAX1 LBD,
consisting of residues V253–E307 and V358–I470. The sites of the
single–amino-acid alterations, in the LBD, causing AHC are labeled.
male or a carrier female, despite the absence of the mu-
tation in her genomic DNA.
Although the frameshift and nonsense mutations are
distributed throughout the N-terminal and C-terminal
portions of DAX1, corresponding to the DNA-binding
domain and the LBD in other nuclear hormone receptors
(Burris et al. 1996), the single–amino-acid changes re-
ported, to date, are found only in the LBD. Each of the
six mutations altering single amino acids (Muscatelli et
al. 1994; Schwartz et al. 1997; Takahashi et al. 1997;
this report) affects residues that are identical in human
DAX1 and mouse Ahch (Guo et al. 1996b; Swain et al.
1996) and, by homology with the three-dimensional
structures of rTRa1 (Wagner et al. 1995) and hRXRa
(Bourguet et al. 1995), map to the hydrophobic core of
the putative DAX1 LBD (fig. 4). The modeling of these
missense and single-codon–deletion mutations provides
us with the opportunity to compare and contrast these
amino acid changes in DAX1 with those in other nuclear
hormone receptors.
The LBD of a typical nuclear hormone receptor par-
ticipates in hormone binding, dimerization, heat-shock
protein-complex formation, and transcriptional activa-
tion and repression (Tsai and O’Malley 1994; Ribeiro
et al. 1995). The three-dimensional structures of the
LBDs in three nuclear hormone receptors, hRXR, rTR,
and hRAR, recently were determined by x-ray crystal-
lography (Bourguet et al. 1995; Wagner et al. 1995;
Wurtz et al. 1996). All three share a common fold con-
sisting of three layers of a-helices, described as an a-
helical sandwich. Furthermore, an apparent subdomain
structure exists in which the LBD may be divided into
two subdomains: a structural subdomain consisting of
H1, H3–H5–H6, H9, H10, and H11, representing the
hydrophobic core of the LBD, and a ligand-binding sub-
domain consisting of H3, S1–2, H7, H8, H11, and H12,
which recognizes and binds the cognate ligand (fig. 4A).
Functionally, the subdomains are implicated in distinct
activities of the receptor: the structural subdomain me-
diates hormone-independent activities such as dimeri-
zation or unliganded repression, whereas the ligand-
binding subdomain mediates hormone-dependent activ-
ities such as transcriptional activation. Mutations in the
TR that result in generalized resistance to thyroid hor-
mone cluster exclusively in the ligand-binding subdo-
main, consistent with a primary defect in hormone-bind-
ing and hormone-dependent processes (Wagner et al.
1995; R. L. Wagner, J. D. Baxter, and R. J. Fletterick,
unpublished data). On the other hand, genetic altera-
tions causing complete–androgen-insensitivity syn-
drome, the most severe form of the disease, include mu-
tations in the structural subdomain (R. L. Wagner, J. D.
Baxter, and R. J. Fletterick, unpublished data). There-
fore, there are two classes of LBD mutations associated
with disease: (1) those that disturb ligand binding and
that are consistent with altered but continued function;
and (2) those that disrupt receptor structure and that
profoundly reduce function.
The clustering of mutations in the DAX1 LBD hy-
drophobic core has definite implications for our under-
standing of the structure and function of this orphan
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nuclear receptor. The absence of DAX1 mutations in
residues, which, by analogy with the structures of the
liganded rTR and hRXR LBDs, would be expected to
bind ligand, suggests either that DAX1 may not be reg-
ulated by ligand or that such mutations may cause a
different phenotype. Alternatively, since DAX1 muta-
tions reside in the structural subdomain, the mutations
might disrupt the ability of DAX1 to dimerize, an ac-
tivity mediated by the structural subdomain. Several
lines of evidence are consistent with this proposal. A
conserved pattern of hydrophobic residues in H11 is
implicated in dimerization, for several receptors (Fawell
et al. 1990). Three of the mutations described here are
expected to affect the structure of H11. In the model of
DAX1, a charge pair between E377 and R425 stabilized
H11 (fig. 4B); an identical charge pair was observed in
the structure of the hRXR LBD, between the homolo-
gous residues E366 and R414, and is predicted to occur
in other receptors, such as the estrogen receptor (ER)
(Bourguet et al. 1995; Wurtz et al. 1996). Mutation of
R503 in the ER, the residue homologous to R425 in
DAX1, eliminates homodimerization in vitro (Fawell et
al. 1990). Both residues in the charge pair are mutated
in DAX1 and are likely to have the same effect.Mutation
of a buried hydrophobic residue in H11 also may elim-
inate dimerization, presumably by alteration of the pack-
ing of H11 (Fawell et al. 1990). Mutation N440I, lead-
ing to a steric clash between H11 and H5–H6, is similar.
However, other results suggest that there is unusual re-
pressor activity near the C-terminus of DAX1, and de-
letions or point mutations in H11 and in other domains
in the putative LBD of DAX1 exhibited impaired inhi-
bition of SF1-mediated transactivation (Ito et al. 1997).
Since the LBD of DAX1 shares limited sequence identity
with other members of the nuclear-receptor superfamily
and even differs from its mouse homologue, deletions
or point mutations in H11 and in other regions of the
putative LBD of DAX1 may cause AHC by mechanisms
other than the elimination of dimerization.
Another region implicated in dimerization is the
H3–H5 loop; for example, mutation of D300 in H5
in hTRb eliminates heterodimerization with RXR
(O’Donnell et al. 1991). The H3–H5 loop contains a
signature sequence motif that is highly conserved in the
nuclear-receptor superfamily. DAX1 mutations R267P
and dV269 immediately precede the conserved motif in
H3 and are comparably disruptive: R267P inserts a he-
lix-breaking proline into H3, and the in-frame deletion
dV269 changes the phase of the helix. Finally, mutations
V385G and A300V change the packing within the hy-
drophobic core of the DAX1 LBD, perturbing its
structure.
Thus, we can speculate that the DAX1 single–amino-
acid mutations may interfere with dimerization or other
activities of DAX1. The closely related orphan receptor
SHP appears to dimerize with the retinoid receptors and
the TR, leading to repression of gene expression (Seol
et al. 1996). The six missense mutations and the single-
codon deletion all map to the structural subdomain in
our model of the DAX1 protein and alter amino acid
residues that are highly conserved and that are predicted
to disrupt receptor folding, dimerization, and overall
DAX1 function in a major way.
In summary, the two-exon structure of theDAX1 gene
facilitates direct sequencing for mutation detection. One
family evidenced gonadal mosaicism, which has impor-
tant genetic-counseling consequences for families with
AHC. Although the majority of the DAX1 mutations
identified by our group and by others are frameshift or
nonsense mutations, seven single–amino-acid changes
have been documented and provide valuable structure-
function insights. The absence of missense mutations in
the N-terminal half of DAX1 and in the putative ligand-
binding subdomain suggests that such mutations may
be associated with different phenotypes. These other
phenotypes may include a variety of possibilities, such
as no clinical findings, isolated HH, or even in utero
lethality.
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